Fulcrum Therapeutics (FULC)
(Delayed Data from NSDQ)
$9.17 USD
+0.38 (4.32%)
Updated Aug 23, 2024 04:00 PM ET
1-Strong Buy of 5 1
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
FULC 9.17 +0.38(4.32%)
Will FULC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FULC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FULC
Here's Why You Should Invest in SpringWorks (SWTX) Stock Now
Alkermes (ALKS) Begins Narcolepsy Type 2 Study on ALKS 2680
FULC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study
Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista
Why Grifols (GRFS) Stock Price Moved Up 7% on Wednesday
Other News for FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer
Fulcrum appoints Isabel Kalofonos as CCO
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Analysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Exact Sciences (EXAS) and Fulcrum Therapeutics (FULC)